CN111035662B - 植物乳杆菌s58在制备用于缓解辛辣食品对消化系统损伤的产品中的应用 - Google Patents
植物乳杆菌s58在制备用于缓解辛辣食品对消化系统损伤的产品中的应用 Download PDFInfo
- Publication number
- CN111035662B CN111035662B CN201911131496.5A CN201911131496A CN111035662B CN 111035662 B CN111035662 B CN 111035662B CN 201911131496 A CN201911131496 A CN 201911131496A CN 111035662 B CN111035662 B CN 111035662B
- Authority
- CN
- China
- Prior art keywords
- lactobacillus plantarum
- beta
- digestive system
- damage
- gastric
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 240000006024 Lactobacillus plantarum Species 0.000 title claims abstract description 68
- 235000013965 Lactobacillus plantarum Nutrition 0.000 title claims abstract description 68
- 229940072205 lactobacillus plantarum Drugs 0.000 title claims abstract description 68
- 230000006378 damage Effects 0.000 title claims abstract description 27
- 210000002249 digestive system Anatomy 0.000 title claims abstract description 20
- 235000021259 spicy food Nutrition 0.000 title claims abstract description 15
- 238000002360 preparation method Methods 0.000 title claims description 10
- 238000004321 preservation Methods 0.000 claims abstract description 16
- 235000013305 food Nutrition 0.000 claims abstract description 12
- 239000003814 drug Substances 0.000 claims abstract description 9
- 229940079593 drug Drugs 0.000 claims abstract description 7
- 230000003405 preventing effect Effects 0.000 claims description 5
- 208000025865 Ulcer Diseases 0.000 abstract description 11
- 231100000397 ulcer Toxicity 0.000 abstract description 11
- 235000002566 Capsicum Nutrition 0.000 abstract description 2
- 239000006002 Pepper Substances 0.000 abstract 1
- 235000016761 Piper aduncum Nutrition 0.000 abstract 1
- 235000017804 Piper guineense Nutrition 0.000 abstract 1
- 244000203593 Piper nigrum Species 0.000 abstract 1
- 235000008184 Piper nigrum Nutrition 0.000 abstract 1
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 39
- 210000001519 tissue Anatomy 0.000 description 37
- 230000000694 effects Effects 0.000 description 28
- 210000002784 stomach Anatomy 0.000 description 25
- RHCSKNNOAZULRK-APZFVMQVSA-N 2,2-dideuterio-2-(3,4,5-trimethoxyphenyl)ethanamine Chemical group NCC([2H])([2H])C1=CC(OC)=C(OC)C(OC)=C1 RHCSKNNOAZULRK-APZFVMQVSA-N 0.000 description 23
- 210000000813 small intestine Anatomy 0.000 description 21
- 229960002504 capsaicin Drugs 0.000 description 19
- 235000017663 capsaicin Nutrition 0.000 description 19
- 108090000193 Interleukin-1 beta Proteins 0.000 description 18
- 102000003777 Interleukin-1 beta Human genes 0.000 description 17
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 16
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 16
- 229920002498 Beta-glucan Polymers 0.000 description 16
- 241000209219 Hordeum Species 0.000 description 16
- 235000007340 Hordeum vulgare Nutrition 0.000 description 16
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 16
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 15
- 230000002496 gastric effect Effects 0.000 description 15
- 230000002829 reductive effect Effects 0.000 description 15
- 210000001035 gastrointestinal tract Anatomy 0.000 description 14
- 206010061218 Inflammation Diseases 0.000 description 13
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 230000004054 inflammatory process Effects 0.000 description 13
- 210000001156 gastric mucosa Anatomy 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 11
- 108020004999 messenger RNA Proteins 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 11
- 102000001301 EGF receptor Human genes 0.000 description 10
- 108060006698 EGF receptor Proteins 0.000 description 10
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 10
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 10
- 239000002158 endotoxin Substances 0.000 description 10
- 230000000968 intestinal effect Effects 0.000 description 10
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 10
- LVRVABPNVHYXRT-BQWXUCBYSA-N 52906-92-0 Chemical compound C([C@H](N)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)C(C)C)C1=CC=CC=C1 LVRVABPNVHYXRT-BQWXUCBYSA-N 0.000 description 9
- 102400001368 Epidermal growth factor Human genes 0.000 description 9
- 101800003838 Epidermal growth factor Proteins 0.000 description 9
- 102400001357 Motilin Human genes 0.000 description 9
- 101800002372 Motilin Proteins 0.000 description 9
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 9
- 229940116977 epidermal growth factor Drugs 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 8
- 102000003896 Myeloperoxidases Human genes 0.000 description 8
- 108090000235 Myeloperoxidases Proteins 0.000 description 8
- 102100028452 Nitric oxide synthase, endothelial Human genes 0.000 description 8
- 101710090055 Nitric oxide synthase, endothelial Proteins 0.000 description 8
- 102000005157 Somatostatin Human genes 0.000 description 8
- 108010056088 Somatostatin Proteins 0.000 description 8
- 208000007107 Stomach Ulcer Diseases 0.000 description 8
- 102400000096 Substance P Human genes 0.000 description 8
- 101800003906 Substance P Proteins 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 201000005917 gastric ulcer Diseases 0.000 description 8
- 210000004907 gland Anatomy 0.000 description 8
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 8
- 229960000553 somatostatin Drugs 0.000 description 8
- 102000004127 Cytokines Human genes 0.000 description 7
- 108090000695 Cytokines Proteins 0.000 description 7
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 7
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 7
- 230000009471 action Effects 0.000 description 7
- 210000002919 epithelial cell Anatomy 0.000 description 7
- 230000002757 inflammatory effect Effects 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 102100037850 Interferon gamma Human genes 0.000 description 6
- 108010074328 Interferon-gamma Proteins 0.000 description 6
- 208000027418 Wounds and injury Diseases 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 230000008595 infiltration Effects 0.000 description 6
- 238000001764 infiltration Methods 0.000 description 6
- 208000014674 injury Diseases 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 102000003940 Occludin Human genes 0.000 description 5
- 108090000304 Occludin Proteins 0.000 description 5
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 description 5
- 102400000015 Vasoactive intestinal peptide Human genes 0.000 description 5
- 230000004888 barrier function Effects 0.000 description 5
- 150000001720 carbohydrates Chemical class 0.000 description 5
- 235000014633 carbohydrates Nutrition 0.000 description 5
- 238000003304 gavage Methods 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 description 5
- 108020004465 16S ribosomal RNA Proteins 0.000 description 4
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 238000012408 PCR amplification Methods 0.000 description 4
- 208000008469 Peptic Ulcer Diseases 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000001079 digestive effect Effects 0.000 description 4
- 210000004969 inflammatory cell Anatomy 0.000 description 4
- 230000006799 invasive growth in response to glucose limitation Effects 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 210000004400 mucous membrane Anatomy 0.000 description 4
- 230000000770 proinflammatory effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 206010064571 Gene mutation Diseases 0.000 description 3
- 238000003794 Gram staining Methods 0.000 description 3
- 241000186660 Lactobacillus Species 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 102000057297 Pepsin A Human genes 0.000 description 3
- 108090000284 Pepsin A Proteins 0.000 description 3
- 239000008186 active pharmaceutical agent Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000002301 combined effect Effects 0.000 description 3
- 208000010643 digestive system disease Diseases 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 230000027119 gastric acid secretion Effects 0.000 description 3
- 239000003629 gastrointestinal hormone Substances 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 229940111202 pepsin Drugs 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000002457 bidirectional effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000008497 endothelial barrier function Effects 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 210000005027 intestinal barrier Anatomy 0.000 description 2
- 210000004347 intestinal mucosa Anatomy 0.000 description 2
- 230000004673 intestinal mucosal barrier function Effects 0.000 description 2
- 230000003870 intestinal permeability Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 230000004682 mucosal barrier function Effects 0.000 description 2
- 230000001338 necrotic effect Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 230000008816 organ damage Effects 0.000 description 2
- 208000011906 peptic ulcer disease Diseases 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229910021642 ultra pure water Inorganic materials 0.000 description 2
- 239000012498 ultrapure water Substances 0.000 description 2
- 101710082233 2,4-diaminopentanoate dehydrogenase Proteins 0.000 description 1
- 206010001488 Aggression Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 240000008574 Capsicum frutescens Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 206010008617 Cholecystitis chronic Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102000010970 Connexin Human genes 0.000 description 1
- 108050001175 Connexin Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010061459 Gastrointestinal ulcer Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 101710141619 Meso-diaminopimelate D-dehydrogenase Proteins 0.000 description 1
- 206010061297 Mucosal erosion Diseases 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- YIKSCQDJHCMVMK-UHFFFAOYSA-N Oxamide Chemical compound NC(=O)C(N)=O YIKSCQDJHCMVMK-UHFFFAOYSA-N 0.000 description 1
- 102400000319 Oxyntomodulin Human genes 0.000 description 1
- 101800001388 Oxyntomodulin Proteins 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 241001052560 Thallis Species 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000001390 capsicum minimum Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000005482 chemotactic factor Substances 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- YOBAEOGBNPPUQV-UHFFFAOYSA-N iron;trihydrate Chemical compound O.O.O.[Fe].[Fe] YOBAEOGBNPPUQV-UHFFFAOYSA-N 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- PXZWGQLGAKCNKD-DPNMSELWSA-N molport-023-276-326 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 PXZWGQLGAKCNKD-DPNMSELWSA-N 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 235000021110 pickles Nutrition 0.000 description 1
- 238000012257 pre-denaturation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 235000021108 sauerkraut Nutrition 0.000 description 1
- 230000009528 severe injury Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000019654 spicy taste Nutrition 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 210000004876 tela submucosa Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000004018 waxing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/169—Plantarum
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Inorganic Chemistry (AREA)
- Zoology (AREA)
- Physiology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了保藏编号为CCTCC NO：M 2019595的植物乳杆菌S58(Lactobacillus plantarumS58)在制备用于缓解辛辣食品对消化系统损伤的保健食品和药品中的应用，不仅扩大了植物乳杆菌S58的应用范围，提高了其利用价值，而且给因喜食辣椒而造成消化系统溃疡的患者的治疗带来了新的希望。
Description
技术领域
本发明涉及一种植物乳杆菌在制备保健食品和药品中的应用。
背景技术
随着川菜和重庆火锅在国内外的迅速流行，食用人群正在不断扩大，火锅中的辛辣味来源于辣椒中的辣椒素。辣椒素是一种含草酰胺的生物碱，其分子式为C18H27NO3，化学名称为(反式)-8-甲基-N-香草基-6-壬烯基酰胺。研究证明，适量的辣椒素摄入具有抗肿瘤、抗镇痛、抗炎以及促进脂肪氧化、减轻体重等作用，但过量辣椒素摄入却会对人体消化系统造成损伤，甚至造成消化道溃疡。因此，辣椒素的最终作用取决于其施用的剂量。
近十年，据不完全估计，消化系统疾病占所有疾病总和的42％，包括消化性溃疡、溃疡性结肠炎、部分慢性胆囊炎及肝炎后综合征等。包括消化道(口、喉、食道、胃、小肠、结肠)和消化辅助器官(胰腺、胆囊和肝脏)的消化系统因为上述各种情况产生不同反应，最终体现为消化系统疾病。全世界每年约有10％的人会得消化系统溃疡，因为它日益增长的高发病率和死亡率，消化系统溃疡已经成为全世界最重要的胃肠道疾病之一，与感染性疾病不同，消化系统溃疡是多因素的，最主要的起因是不健康的生活方式和不同的危险因素，如物理化学性损伤或生物性损伤。作为消化系统抵御外界侵扰的第一道屏障，胃、肠道最容易受到饮食和药物的影响。因此，在尽量避免服用药物对身体造成不必要的负担的情况下，寻找一种食药两用的物质来保护消化系统就显得尤为重要。
乳酸菌与人体健康息息相关，具有维持肠道菌群的微生态平衡、保护胃肠粘膜屏障，加强机体免疫功能、预防和抑制肿瘤发生、提高食物营养的利用率、促进食品中营养的吸收、降低胆固醇、延缓机体衰老、预防龋齿、抑制病原菌生长等功效。独特的生物学特性和益生功能使得乳酸菌在农业、食品及医疗保健等领域具有广泛的应用前景和利用价值。
发明内容
本发明的目的在于提供一种从泡菜中分离得到的植物乳杆菌，利用其对消化道溃疡的缓解效果，以开发食品、药品和功能保健制品。
经研究，本发明提供如下技术方案：
本发明公开了一种植物乳杆菌S58的应用，所述植物乳杆菌S58在制备用于治疗或预防辛辣食品对消化系统损伤的药物中的应用，其中，所述植物乳杆菌S58(LactobacillusplantarumS58)的保藏编号为CCTCC NO：M 2019595。
本发明公开了一种植物乳杆菌S58的应用，所述植物乳杆菌S58在制备用于缓解辛辣食品对消化系统损伤的食品中的应用，其中，所述植物乳杆菌S58(LactobacillusplantarumS58)的保藏编号为CCTCC NO：M 2019595。
本发明公开了一种植物乳杆菌S58的应用，所述植物乳杆菌S58在制备用于缓解辛辣食品对消化系统损伤的保健品中的应用，其中，所述植物乳杆菌S58(LactobacillusplantarumS58)的保藏编号为CCTCC NO：M 2019595。
本发明还公开了一种用于治疗或预防辛辣食品对消化系统损伤的药物组合物，所述药物组合物中含有保藏编号为CCTCC NO：M 2019595的药学有效剂量的植物乳杆菌S58。
本发明还公开了一种用于缓解辛辣食品对消化系统损伤的食品，所述食品中含有保藏编号为CCTCC NO：M 2019595的植物乳杆菌S58。
本发明还公开了一种用于缓解辛辣食品对消化系统损伤的保健品，所述保健品中含有保藏编号为CCTCC NO：M 2019595的植物乳杆菌S58。
本发明还公开了一种用于缓解辛辣食品对消化系统损伤的食品添加剂，所述食品添加剂中含有保藏编号为CCTCC NO：M 2019595的植物乳杆菌S58。
辣椒素诱导消化系统溃疡模型小鼠结果显示：植物乳杆菌S58能够有效的抑制胃溃疡的面积；能够在一定程度上缓解胃黏膜表层结构的损伤，使腺体排列较为有序，使上皮细胞浸润较少，使腺腔内坏死减少，使炎症和淋巴细胞溶出减少；能够使小肠绒毛绝大部分保持正常形态，炎性细胞浸润现象消失，水肿现象消失；能够使血清MTL、SP、IL-1β、TNF-α、IFN-γ、LPS、MPO、sICAM-1含量减少，使SS含量增加，缓解炎症；能够使小鼠胃组织中EGF、EGFR、VEGF基因的表达量上升，促进溃疡的愈合，介导上皮细胞的自我修复作用，减少胃酸的分泌；能够使胃、小肠组织中NF-KB、TNF-α、IL-1β的表达量下降，IKB-α的表达量升高，减轻胃肠道的炎症反应；能够降低胃组织iNOS表达量，增加eNOS表达量，从而抑制炎症反应，保护胃黏膜，抑制胃溃疡；能够使ZO-1的表达量显著上升，修复肠粘膜屏障。因此，植物乳杆菌S58能在一定程度上缓解辣椒素造成的胃肠道溃疡。
本发明的有益效果在于：本发明提供了保藏编号为CCTCC NO：M 2019595的植物乳杆菌S58(Lactobacillus plantarumS58)在制备缓解辛辣食品对消化系统损伤的保健食品和药品中的应用，不仅扩大了植物乳杆菌S58的应用范围，提高了其利用价值，而且给治疗消化系统疾病带来了新的希望。
保藏信息
中国典型培养物保藏中心；地址：中国武汉武汉大学；保藏日期：2019年8月1日；保藏编号：CCTCC NO：M 2019595；分类命名：植物乳杆菌S58(Lactobacillus plantarumS58)。
附图说明
图1为分离菌株菌落形态(a)及革兰氏染结果(b)
图2为植物乳杆菌S58的API 50CH反应结果
图3为胃组织图片
图4为胃组织病理学观察
图5为小肠组织病理学观察
图6为胃组织中EGF、EGFR、VEGF mRNA的表达
图7为胃组织中NF-KB、IKB-α、TNF-α、IL-1βmRNA的表达
图8为胃组织中iNOS、eNOS mRNA的表达
图9为小肠组织中NF-KB、IKB-α、TNF-α、IL-1βmRNA的表达
图10为小肠组织中ZO-1、Occludin mRNA的表达
上述图中，标有相同小写英文字母(a、b、c)的组之间不存在显著差异(p＞0.05)；标有不同小写英文字母(a、b、c)的组之间存在显著差异(p<0.05)。
具体实施方式
为了使本发明的目的、技术方案和优点更加清楚，下面将结合附图对本发明的优选实施例进行详细的描述。
一、植物乳杆菌S58的分离与鉴定
1实验材料
重庆市农家自然发酵泡菜。
2实验方法
2.1乳酸菌的分离纯化
将取回的泡菜水进行10倍梯度稀释，依次稀释至10-7。选择4个适宜稀释度(稀释度为10-4、10-5、10-6、10-7)分别取100μL涂布在MRS固体平板上，37℃培养48h后，选取形态各异的单菌落采用平板划线法分离菌株。重复上述步骤直至得到纯化菌株，通过革兰氏染色进行形态学观察。
2.2 PCR扩增16S rDNA序列
采用细菌基因组DNA提取试剂盒提取纯化菌株的DNA。采用25μL反应体系进行PCR扩增：模板DNA 1μL、上游引物(10μM)1μL、下游引物(10μM)1μL、2×Taq PCR Master Mix12.5μL，用无菌超纯水补足至25μL。PCR扩增条件：94℃预变性5min；94℃变性1.5min，55℃退火1min，72℃延伸1.5min，共30个循环；72℃末端延伸10min。最后委托华大基因科技有限公司对检测合格的PCR扩增产物进行双向测序，测序结果通过NCBI中的BLAST程序进行同源性比对分析。
2.3 API试剂盒鉴定
分离菌株在37℃培养18h，于3000r/min、15min的条件下离心收集菌体，用无菌生理盐水洗涤菌体后重悬为菌悬液。参考API试剂盒说明书进行操作。
3结果与分析
3.1分离菌株的菌落形态和细胞形态
菌株纯化后在MRS培养基中形成单菌落，菌落形态几乎一致，大多数呈圆形，白色，表面光滑湿润。革兰氏染色后在显微镜下观察到紫色细胞形态，判定为革兰氏阳性菌(G+)。菌株的菌落形态和革兰氏染色结果见图1。
3.2菌株16S rDNA序列分析
16S rDNA同源性分析结果显示，与Gene Bank数据库中已知植物乳杆菌(Lactobacillus plantarum)的同源性达100％。植物乳杆菌S58的16S rDNA基因扩增产物的双向序列如SEQ ID No.1所示。
3.3菌株生化特性鉴定结果
乳酸杆菌种水平的表型鉴定主要依据碳水化合物发酵试验。API50CH试剂盒是通过菌株对49种不同碳水化合物的利用情况来进行鉴定。
图2示出了实验菌株的API 50CH反应结果。表1示出了该菌株对49种碳水化合物发酵试验结果。由图2和表1可知，在供试的49种碳源中，该菌株可以利用其中26种碳水化合物。经API lab plus系统最终鉴定，实验菌株为植物乳杆菌(Lactobacillus plantarum)，其ID值为99.90％，T值为0.65，达到鉴定要求(ID值≥99.0％且T值≥0.5)。
表1 Lactobacillus plantarumS58对49种碳水化合物发酵试验结果
注：“+”代表反应阳性；“－”代表反应阴性。
二、植物乳杆菌S58联合青稞β-葡聚糖对小鼠消化道溃疡的缓解作用
1实验材料
天然辣椒素(纯度为95％)，购自河南倍特生物科技有限公司
实验菌株为植物乳杆菌S58(Lactobacillus plantarumS58)，保藏编号为CCTCCNo：M 2019595。
青稞β-葡聚糖，(纯度为71.2％)，购自西安通泽生物科技有限公司。
实验动物为6周龄雄性昆明小鼠，购自重庆恩斯维尔生物科技有限公司。饲养于室温25±2℃、相对湿度50±5％、12h光照/12h黑暗的标准化实验室中，适应性喂养一周后开始实验。
2实验方法
2.1实验动物分组及处理
取昆明成年雄性小鼠50只，随机分成五组，每组10只。造模期间自由饮食饮水。造模及给药方式如下表(因天然辣椒素不易溶于水，易溶于有机溶剂，故溶解辣椒素的溶剂选择大豆油)：
表2动物造模及给药方式
实验期间每3天称量一次体重，调整灌胃量。4周末，收集各组小鼠粪便，所有小鼠禁食不禁水18h，摘眼球取血，于4℃、3000r/min离心10min收集血清，-80℃保存备用；取血后脱颈椎处死，解剖取出胃组织、小肠组织，将胃组织沿胃大弯剪开铺平，迅速拍照；剪取适量大小胃组织、小肠组织，立即放入10％福尔马林溶液中固定48h；然后将所有组织置于液氮中冷冻，最终放入-80℃保存。
2.2组织切片观察
固定好的组织经脱水、透明、浸蜡、包埋、切片后进行HE染色，最后在光学显微镜下观察组织形态变化。
2.3血清指标的测定
按照试剂盒说明书对小鼠血清中MTL、SP、SS、VIP、IL-6、IL-1β、TNF-α、IFN-γ、LPS、MPO、sICAM-1含量进行测定。
2.4 qPCR测定胃组织、小肠组织中mRNA的表达
按照Trizol(Invitrogen，美国加利福尼亚州卡尔斯巴德)说明书提取结肠总RNA，取RNA样品1μL，加入1μL(oligo)primer dT，10μL无菌超纯水，混合物于65℃反应5min；反应完成后，在反应体系中加入1μL Ribolock RNase Inhibitor、2μL 100mM dNTP mix、4μL 5×Reaction buffer和1μL Revert AidM-mu/v RT，混合均匀后，在42℃、60min和70℃、5min条件下合成cDNA，用超微量分光光度计测定总DNA的纯度和浓度，然后将每个样本的DNA浓度调整到同一水平(1μg/μL)；接着以表2所述引物序列对目标基因进行反转录和扩增。反应条件为：95℃变性15min，60℃退火1h，95℃延伸15min，总共40个循环；最后以DAPDH作为持家基因，通过2-ΔΔCT计算目的基因的相对表达量。
表3实验中用到的引物序列
3实验结果与分析
3.1植物乳杆菌S58联合青稞β-葡聚糖对小鼠胃组织形态的影响
胃组织照片能直观的观察到胃部溃疡情况，如图3所示，NC组小鼠胃黏膜表面外观良好，无明显黏膜糜烂情况，胃部颜色鲜艳且具有光泽；CAP组小鼠胃黏膜层糜烂严重，完整性破坏，黏膜下层充血，无光泽。β-D组、LP.S58组、LP.S58+β-D组从表观胃的溃疡面积来看，均有效抑制胃溃疡的面积，与对照组相比，胃溃疡面积明显缩小，说明LP.S58对辣椒素造成的胃溃疡有一定的保护作用，且与β-D联合作用效果更好。
3.2植物乳杆菌S58联合青稞β-葡聚糖对小鼠胃组织病理学形态的影响
胃切片是除胃部图片之外，另一种直观表达辣椒素对胃组织损伤程度的方式。从图4中能看出，正常组小鼠胃壁四层结构清楚，上皮深层结构完整、连续，腺体结构排列整齐，胃黏膜上表皮细胞完整，无细胞浸润和炎症。CAP组小鼠胃黏膜表层结构破损严重且深达肌层，其缺口处无再生粘膜覆盖，其胞体排列紊乱且呈囊状扩张，腺体结构紊乱，上皮细胞浸润、炎症、淋巴细胞溶出，腺腔内出现坏死细胞。LP.S58、β-D在一定程度上缓解了胃黏膜表层结构的损伤，腺体排列较为有序，上皮细胞浸润较少，腺腔内少量细胞坏死，炎症和淋巴细胞溶出减少。其中LP.S58+β-D组预防效果优于其单独作用组，说明LP.S58能在一定程上保护被辣椒素破坏的胃黏膜组织。
3.3植物乳杆菌S58联合青稞β-葡聚糖对小鼠小肠组织病理学形态的影响
小肠绒毛的完整性与肠道蠕动的能力密切相关。灌胃辣椒素容易引起小肠绒毛机能的退化，甚至引起小肠绒毛的断裂、萎缩现象。如图5所示，NC组小鼠的小肠绒毛完整且整齐、排列有序，小肠壁厚度适中；CAP组小鼠的小肠受到严重损伤，其绒毛断裂、缺失，绒毛变稀疏，小肠壁明显变薄，出现严重的炎性细胞浸润现象，小肠组织出现水肿现象；单一LP.S58、β-D作用并没有使小肠的损伤得到明显的改善，但LP.S58与β-D的联合作用使小肠损伤状况得到了改善，LP.S58+β-D组小肠绒毛绝大部分保持正常形态，炎性细胞浸润现象消失，水肿现象消失。
3.4植物乳杆菌S58联合青稞β-葡聚糖对小鼠血清指标MTL、SP、SS、VIP的影响
当胃黏膜屏障受损时，强腐蚀性的胃酸以及胃蛋白酶可使胃黏膜与组织发生严重损伤。胃肠激素是调节胃液分泌的重要影响因素。胃动素(MTL)、P物质(SP)属于兴奋性胃肠激素，在应激作用下含量会升高，引起胃液大量分泌使胃内部呈强酸性，致使胃黏膜组织发生损伤。生长抑素(SS)、血管活性肠肽(VIP)属于抑制性胃肠激素，能抑制胃液分泌,其中SS能通过抑制MTL和胃蛋白酶的释放来保护胃黏膜，促进胃损伤部位愈合。与NC组相比，CAP组小鼠血清MTL含量和SP含量显著升高，SS含量显著降低。与CAP组相比，LP.S58组与LP.S58+β-D组血清MTL和SP水平显著降低，且LP.S58+β-D组下降的更明显；LP.S58组与LP.S58+β-D组血清SS水平显著上升，且LP.S58+β-D组上升的更明显；所有组的VIP水平都不具有显著性差异。
表4植物乳杆菌S58联合青稞β-葡聚糖对小鼠胃肠激素的影响
3.5植物乳杆菌S58联合青稞β-葡聚糖对小鼠血清指标IL-6、IL-1β、TNF-α、IFN-γ的影响
炎症反应产生的促炎细胞因子数量与消化道溃疡的严重程度有关，并可能进一步增加细胞和器官的损伤。IL-1β主要由单核巨噬细胞产生，可以引起肠道炎症和局部并发症。有研究表明，IL-6作为趋化因子能够趋化多种单核细胞和炎性细胞，促进炎性介质的产生和释放，破坏消化道黏膜屏障，引起消化道黏膜炎性损伤加重。IFN-γ在溃疡组织表达明显升高，同时IFN-γ也与黏膜细胞的凋亡呈正相关。与IFN-γ起协同作用的TNF-α在消化道溃疡中也具有多种病理生理作用，包括促使细胞凋亡、中性粒细胞浸润，引起细胞骨架瓦解，脯氨酸、酪氨酸激酶的活化，它还能促进氧自由基和其他促炎细胞因子的释放，并导致器官损伤和细胞膜稳定性的破坏，导致胃肠组织损伤。在本实验中发现，IL-1β、TNF-α和IFN-γ水平在CAP组中最高，NC组最低；LP.S58组、β-D组、LP.S58+β-D组相比于CAP组来说IL-1β、TNF-α和IFN-γ水平显著降低；但各组的IL-6水平没有显著差异。LP.S58与β-D能减少细胞因子和炎症因子的产生从而预防消化道溃疡。
表5植物乳杆菌S58联合青稞β-葡聚糖对小鼠炎症因子的影响
3.6植物乳杆菌S58联合青稞β-葡聚糖对小鼠血清指标LPS、MPO、sICAM-1的影响
致病性肠道菌群刺激肠道上皮细胞的内毒素(LPS)产生和释放，同时，肠道菌群的紊乱造成了肠粘膜屏障受损，肠道通透性增加，从而使LPS轻松通过肠道粘膜层进入血液，随后LPS可以与细胞因子受体结合，从而引发促炎细胞因子的释放。髓过氧化物酶(MPO)，可以通过活化NF-KB等信号通路，使细胞因子及粘附分子增多，使白细胞更容易穿透内皮屏障，到达炎症组织，促进炎症反应。细胞间粘附分子(sICAM-1)，能与特异性受体结合，可影响白细胞等与内皮细胞之间的粘附作用，使其粘附作用增强，活化内皮细胞，使其更容易穿透内皮屏障转移到损伤和炎症部位。如表6所示，灌胃辣椒素使LPS、MPO、sICAM-1水平显著上升，LP.S58、β-D以及二者的共同作用均能显著的降低血清LPS、MPO、sICAM-1水平，且二者联合作用效果更好。
表6植物乳杆菌S58联合青稞β-葡聚糖对小鼠LPS、MPO、sICAM-1水平的影响
3.7植物乳杆菌S58联合青稞β-葡聚糖对小鼠胃组织中EGF、EGFR、VEGF mRNA表达的影响
皮生长因子(EGF)主要功能是促进细胞增生，参与胃肠道上皮细胞的增殖分化活动，能够调节胃肠道的生长发育，保护胃肠道，促进黏膜细胞迁移进入新生肉芽组织，修复黏膜损伤部位中的腺体结构，释放多种保护因子。有研究发现EGF能抑制胃酸和胃蛋白酶的分泌，促进RNA和DNA合成介导蛋白质，从而保护胃黏膜。血管内皮生长因子(VEGF)能诱导血管内皮增殖和迁徙，增加血管通透性，在重建和新生血管活动中起到重要作用。有研究表明，VEGF能促进胃肠黏膜上皮细胞增殖分化，显著提升胃黏膜血流量，维持肠道的完整性。表皮生长因子受体(EGFR)能介导EGF的相关作用，广泛存在于哺乳动物及人类的胃肠当中。EGFR在溃疡组织周围能介导转化生长因子，促进溃疡的愈合，介导上皮细胞的自我修复作用，减少胃酸的分泌。
图6表示LP.S58、β-D对胃中EGF、EGFR、VEGF表达的影响，由图可知，与NC组相比，CAP组小鼠胃组织EGF、EGFR、VEGF的表达量均显著降低，而LP.S58、β-D处理组均可以使EGF、EGFR、VEGF的表达量有一定程度的上升，二者的共同作用则可以使EGF、EGFR、VEGF的表达量达到与NC组相当的水平。
3.8植物乳杆菌S58联合青稞β-葡聚糖对小鼠胃组织中NF-KB、IKB-α、TNF-α、IL-1βmRNA表达的影响
在促炎细胞因子中，NF-KB是炎症中重要的信号转录因子，是许多信号传导途径的汇聚点，NF-KB p50、NF-KB p65和IKB结合形成三聚体，从而都以无活性形式存在与细胞介质中。当细胞受到外界刺激时IKB发生磷酸化并降解，此时NF-KB被激活，进入细胞核内，与靶基因相应部位结合，开始相关基因的转录工作。NF-KB可诱导多种细胞因子和炎症因子的生成，如TNF-α、IL-1β等。
图7示出了LP.S58、β-D对胃中NF-KB、IKB-α、TNF-α、IL-1β表达的影响。与NC组相比，CAP组NF-KB、TNF-α、IL-1β的表达量显著上升，IKB-α表达量显著下降；单一LP.S58、β-D进行干预后，NF-KB、TNF-α、IL-1β的表达量有一定程度的下降，IKB-α则有一定程度的升高，但二者的单一作用不及二者的联合作用。
3.9植物乳杆菌S58联合青稞β-葡聚糖对小鼠胃组织中iNOS、eNOS mRNA表达的影响
iNOS和eNOS分别是NOS的诱导型和内皮型，NOS是NO合成的限速酶，在人体和动物的正常组织中广泛存在。eNOS的表达和活性相对稳定，来源于eNOS的NO主要参与促进黏膜上皮修复、调节胃黏膜血流量和适应性细胞保护、抑制胃酸分泌、增强黏液屏障功能以及促进血管再生。iNOS一旦被激活，酶活力持续时间长，会产生大量NO。低浓度NO能有效对抗基因突变，激活机体防御能力，但高浓度NO会失去对基因突变的控制，刺激基因突变，诱发肿瘤。
由图8可知，除CAP组外，其余四组iNOS均显示出低表达量，eNOS均显示出高表达量，且具有显著性差异。说明LP.S58、β-D能降低iNOS表达量，增加eNOS表达量，从而抑制炎症反应，保护胃黏膜，抑制胃溃疡。
3.10植物乳杆菌S58联合青稞β-葡聚糖对小鼠小肠组织中NF-KB、IKB-α、TNF-α、IL-1βmRNA表达的影响
由图9可知，灌胃辣椒素能使小肠组织NF-KB、TNF-α、IL-1β基因的表达量显著上升，IKB-α表达量显著下降；经过LP.S58、β-D干预后，NF-KB、TNF-α、IL-1β的表达量显著下降，IKB-α表达量显著上升，且二者联合作用效果更好。说明LP.S58、β-D能缓解辣椒素造成的小肠组织的炎性损伤。
3.10植物乳杆菌S58联合青稞β-葡聚糖对小鼠小肠组织中ZO-1、Occludin mRNA表达的影响
ZO-1、Occludin是肠道中重要的机密连接蛋白，在维持小肠组织肠道粘膜屏障完整方面起着重要的作用。
由图10可知，灌胃辣椒素后，ZO-1、Occludin的表达量显著下降，说明辣椒素能破坏肠粘膜屏障，使肠道通透性改变；LP.S58与β-D的共同作用能使ZO-1的表达量显著上升，然后，其共同作用却并不能升高Occludin的表达量。
最后说明的是，以上实施例仅用以说明本发明的技术方案而非限制，尽管通过参照本发明的优选实施例已经对本发明进行了描述，但本领域的普通技术人员应当理解，可以在形式上和细节上对其作出各种各样的改变，而不偏离所附权利要求书所限定的本发明的精神和范围。
SEQUENCE LISTING
<110> 西南大学
<120> 植物乳杆菌S58在制备用于缓解辛辣食品对消化系统损伤的产品中的应用
<130> 4
<160> 1
<170> PatentIn version 3.3
<210> 1
<211> 1928
<212> DNA
<213> 植物乳杆菌S58（Lactobacillus plantarumS58）
<400> 1
gggatgcgca tgctatacat gcagtcgaac gaactctggt attgattggt gcttgcatca 60
tgatttacat ttgagtgagt ggcgaactgg tgagtaacac gtgggaaacc tgcccagaag 120
cgggggataa cacctggaaa cagatgctaa taccgcataa caacttggac cgcatggtcc 180
gagtttgaaa gatggcttcg gctatcactt ttggatggtc ccgcggcgta ttagctagat 240
ggtggggtaa cggctcacca tggcaatgat acgtagccga cctgagaggg taatcggcca 300
cattgggact gagacacggc ccaaactcct acgggaggca gcagtaggga atcttccaca 360
atggacgaaa gtctgatgga gcaacgccgc gtgagtgaag aagggtttcg gctcgtaaaa 420
ctctgttgtt aaagaagaac atatctgaga gtaactgttc aggtattgac ggtatttaac 480
cagaaagcca cggctaacta cgtgccagca gccgcggtaa tacgtaggtg gcaagcgttg 540
tccggattta ttgggcgtaa agcgagcgca ggcggttttt taagtctgat gtgaaagcct 600
tcggctcaac cgaagaagtg catcggaaac tgggaaactt gagtgcagaa gaggacagtg 660
gaactccatg tgtagcggtg aaatgcgtag atatatggaa gaacaccagt ggcgaaggcg 720
gctgtctggt ctgtaactga cgctgaggct cgaaagtatg ggtagcaaac aggattagat 780
accctggtag tccataccgt aaacgatgaa tgctaagtgt tggagggttt ccgcccttca 840
gtgctgcagc taacgcatta agcattccgc ctggggagta cggccgcaag gctgaaactc 900
aaaggaattg acgggggccc gcacaagcgg tggagcatgt ggtttaattc gaaggaatct 960
gtcacttagg cggctggttc ctaaaaggtt accccaccga ctttgggtgt tacaaactct 1020
catggtgtga cgggcggtgt gtacaaggcc cgggaacgta ttcaccgcgg catgctgatc 1080
cgcgattact agcgattccg acttcatgta ggcgagttgc agcctacaat ccgaactgag 1140
aatggcttta agagattagc ttactctcgc gagttcgcaa ctcgttgtac catccattgt 1200
agcacgtgtg tagcccaggt cataaggggc atgatgattt gacgtcatcc ccaccttcct 1260
ccggtttgtc accggcagtc tcaccagagt gcccaactta atgctggcaa ctgataataa 1320
gggttgcgct cgttgcggga cttaacccaa catctcacga cacgagctga cgacaaccat 1380
gcaccacctg tatccatgtc cccgaaggga acgtctaatc tcttagattt gcatagtatg 1440
tcaagacctg gtaaggttct tcgcgtagct tcgaattaaa ccacatgctc caccgcttgt 1500
gcgggccccc gtcaattcct ttgagtttca gccttgcggc cgtactcccc aggcggaatg 1560
cttaatgcgt tagctgcagc actgaagggc ggaaaccctc caacacttag cattcatcgt 1620
ttacggtatg gactaccagg gtatctaatc ctgtttgcta cccatacttt cgagcctcag 1680
cgtcagttac agaccagaca gccgccttcg ccactggtgt tcttccatat atctacgcat 1740
ttcaccgcta cacatggagt tccactgtcc tcttctgcac tcaagtttcc cagtttccga 1800
tgcacttctt cggttgagcc gaaggctttc acatcagact taaaaaaccg cctgcgctcg 1860
ctttacgccc aataaatccg gacaacgctt gccacctacg tattaccgcg gctgctggca 1920
cgtagtta 1928
Claims (3)
1.一种植物乳杆菌(Lactobacillusplantarum)S58的应用，其特征在于：所述植物乳杆菌S58在制备用于治疗或预防辛辣食品对消化系统损伤的药物中的应用，其中，所述植物乳杆菌S58的保藏编号为CCTCCNO：M2019595。
2.一种植物乳杆菌(Lactobacillusplantarum)S58的应用，其特征在于：所述植物乳杆菌S58在制备用于缓解辛辣食品对消化系统损伤的食品中的应用，其中，所述植物乳杆菌S58的保藏编号为CCTCCNO：M2019595。
3.一种植物乳杆菌(Lactobacillusplantarum)S58的应用，其特征在于：所述植物乳杆菌S58在制备用于缓解辛辣食品对消化系统损伤的保健品中的应用，其中，所述植物乳杆菌S58的保藏编号为CCTCCNO：M2019595。
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911131496.5A CN111035662B (zh) | 2019-11-19 | 2019-11-19 | 植物乳杆菌s58在制备用于缓解辛辣食品对消化系统损伤的产品中的应用 |
| US16/950,323 US20210145904A1 (en) | 2019-11-19 | 2020-11-17 | Use of Lactobacillus Plantarum S58 in Preparation of Product for Alleviating Spicy Food-Induced Damage to Digestive System |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911131496.5A CN111035662B (zh) | 2019-11-19 | 2019-11-19 | 植物乳杆菌s58在制备用于缓解辛辣食品对消化系统损伤的产品中的应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111035662A CN111035662A (zh) | 2020-04-21 |
| CN111035662B true CN111035662B (zh) | 2023-03-07 |
Family
ID=70232189
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911131496.5A Active CN111035662B (zh) | 2019-11-19 | 2019-11-19 | 植物乳杆菌s58在制备用于缓解辛辣食品对消化系统损伤的产品中的应用 |
Country Status (2)
| Country | Link |
|---|---|
| US (1) | US20210145904A1 (zh) |
| CN (1) | CN111035662B (zh) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110684701B (zh) * | 2019-11-19 | 2021-02-12 | 西南大学 | 植物乳杆菌s58及其在制备用于缓解肥胖的产品中的应用 |
| CN111690565A (zh) * | 2020-07-02 | 2020-09-22 | 重庆第二师范学院 | 一种益生菌及其在胃损伤中的应用 |
| CN116004475B (zh) * | 2023-02-15 | 2024-05-03 | 生合生物科技（扬州）有限公司 | 一株用于预防、辅助治疗胃部虚寒的植物乳杆菌及其应用 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6132710A (en) * | 1997-03-17 | 2000-10-17 | Probiotix, Inc. | Preventing/treating neonatal NEC by administering lactobacillus salivarius and lactobacillus plantarum or a combination thereof |
| CN1985854A (zh) * | 2006-12-22 | 2007-06-27 | 上海交大昂立股份有限公司 | 一种含有植物乳杆菌的组合物及其在增强肠道免疫屏障中的应用 |
| CN105343133A (zh) * | 2015-12-08 | 2016-02-24 | 东北农业大学 | 一种治疗溃疡性结肠炎的复合益生菌、药物及其制备方法 |
| CN107412272A (zh) * | 2017-04-20 | 2017-12-01 | 吉林省农业科学院 | 植物乳杆菌在预防肠道屏障损伤中的应用 |
| CN109770146A (zh) * | 2019-01-18 | 2019-05-21 | 广东微量元素生物科技有限公司 | 一种辅助修复胃粘膜的益生菌微晶粉冲剂及其制备方法 |
-
2019
- 2019-11-19 CN CN201911131496.5A patent/CN111035662B/zh active Active
-
2020
- 2020-11-17 US US16/950,323 patent/US20210145904A1/en not_active Abandoned
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6132710A (en) * | 1997-03-17 | 2000-10-17 | Probiotix, Inc. | Preventing/treating neonatal NEC by administering lactobacillus salivarius and lactobacillus plantarum or a combination thereof |
| CN1985854A (zh) * | 2006-12-22 | 2007-06-27 | 上海交大昂立股份有限公司 | 一种含有植物乳杆菌的组合物及其在增强肠道免疫屏障中的应用 |
| CN105343133A (zh) * | 2015-12-08 | 2016-02-24 | 东北农业大学 | 一种治疗溃疡性结肠炎的复合益生菌、药物及其制备方法 |
| CN107412272A (zh) * | 2017-04-20 | 2017-12-01 | 吉林省农业科学院 | 植物乳杆菌在预防肠道屏障损伤中的应用 |
| CN109770146A (zh) * | 2019-01-18 | 2019-05-21 | 广东微量元素生物科技有限公司 | 一种辅助修复胃粘膜的益生菌微晶粉冲剂及其制备方法 |
Non-Patent Citations (2)
| Title |
|---|
| Qingke β-glucan synergizes with a β-glucan-utilizing Lactobacillus strain to relieve capsaicin-induced gastrointestinal injury in mice;Tian Tang等;《International Journal of Biological Macromolecules》;20210129;第174卷;289–299 * |
| 植物乳杆菌Sc52对脂多糖诱导小鼠肠道屏障损伤的保护作用;何忠梅等;《食品科学》;20181231;第39卷(第09期);134-139 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111035662A (zh) | 2020-04-21 |
| US20210145904A1 (en) | 2021-05-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111035662B (zh) | 植物乳杆菌s58在制备用于缓解辛辣食品对消化系统损伤的产品中的应用 | |
| Meng et al. | Chinese yam peel enhances the immunity of the common carp (Cyprinus carpio L.) by improving the gut defence barrier and modulating the intestinal microflora | |
| KR102128287B1 (ko) | 아커만시아 뮤시니필라 eb-amdk19 균주 및 그의 용도 | |
| Davoodvandi et al. | Effects of therapeutic probiotics on modulation of microRNAs | |
| Liu et al. | Lactobacillus casei LH23 modulates the immune response and ameliorates DSS-induced colitis via suppressing JNK/p-38 signal pathways and enhancing histone H3K9 acetylation | |
| EP4019036A1 (en) | Reg3alpha for use in the protection of oxygen sensitive gram-positive bacteria | |
| Lim et al. | Lactobacillus fermentum IM12 attenuates inflammation in mice by inhibiting NF-κB-STAT3 signalling pathway | |
| Li et al. | Protective effects of a novel Lactobacillus rhamnosus strain with probiotic characteristics against lipopolysaccharide-induced intestinal inflammation in vitro and in vivo | |
| CN110684701B (zh) | 植物乳杆菌s58及其在制备用于缓解肥胖的产品中的应用 | |
| Yao et al. | Effects of probiotics on Toll‑like receptor expression in ulcerative colitis rats induced by 2, 4, 6‑trinitro‑benzene sulfonic acid | |
| CN112646744B (zh) | 一株罗伊氏乳杆菌在预防和缓解溃疡性结肠炎中的应用 | |
| KR102128289B1 (ko) | 아커만시아 뮤시니필라 eb-amdk27 균주 및 그의 용도 | |
| Pang et al. | Lactobacillus rhamnosus from human breast milk ameliorates ulcerative colitis in mice via gut microbiota modulation | |
| CN114657083A (zh) | 一种乳酸菌发酵乳 | |
| Li et al. | Probiotic fermentation of Ganoderma lucidum fruiting body extracts promoted its immunostimulatory activity in mice with dexamethasone-induced immunosuppression | |
| CN117143766A (zh) | 一株修复肠神经的副干酪乳杆菌及其应用 | |
| Cao et al. | Anti-inflammatory and antioxidant activities of probiotic powder containing Lactobacillus plantarum 1.2567 in necrotic enteritis model of broiler chickens | |
| Ma et al. | Poly-β-hydroxybutyrate alleviated diarrhea and colitis via Lactobacillus johnsonii biofilm-mediated maturation of sulfomucin | |
| Liu et al. | Pediococcus pentosaceus PR-1 modulates high-fat-died-induced alterations in gut microbiota, inflammation, and lipid metabolism in zebrafish | |
| CN114107088B (zh) | 一种罗伊氏乳杆菌lrsy523及其应用 | |
| CN113005060B (zh) | 青春双歧杆菌ccfm1173在制备功能性菌剂、食品和或药物中的应用 | |
| CN112121068B (zh) | 约氏乳杆菌在预防和/或治疗炎性肠病中的应用 | |
| CN115364125A (zh) | 一种携带内皮抑素蛋白的重组长双歧杆菌在制备治疗小鼠结肠炎和结直肠癌的药物中的应用 | |
| CN110452830B (zh) | 发酵乳杆菌菌株及其应用 | |
| Wu et al. | Antiobesity Effect of Lacticaseibacillus paracasei LM‐141 on High‐Fat Diet‐Induced Rats through Alleviation of Inflammation and Insulin Resistance |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |